SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $392 | -30.6% | 27,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $565 | -64.1% | 27,000 | -63.9% | 0.00% | 0.0% |
| Q1 2023 | $1,575 | +148.8% | 74,700 | +200.0% | 0.00% | -33.3% |
| Q4 2022 | $633 | -99.9% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $598,000 | +24.8% | 24,900 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $479,000 | +17.4% | 24,900 | +6.0% | 0.00% | +100.0% |
| Q1 2022 | $408,000 | +3038.5% | 23,500 | +1466.7% | 0.00% | – |
| Q4 2017 | $13,000 | -23.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2017 | $17,000 | -15.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2017 | $20,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $20,000 | +100.0% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $10,000 | -54.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $22,000 | +46.7% | 1,500 | -6.2% | 0.00% | – |
| Q2 2016 | $15,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |